Arca
Skip to content
Tools
Tools

CD274: Programmed cell death 1 ligand 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Plays a critical role in induction and maintenance of immune tolerance to self.

  • Drugs that act on it: 13
  • Approved: 5
  • In phases 1 to 3: 8
  • Sponsors: 12

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD274, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Protein or peptide
  • Other

Approved5

  • Durvalumab
  • Atezolizumab
  • Avelumab
  • Sugemalimab
  • Cosibelimab

Phase 35

  • Adebrelimab
  • Envafolimab
  • Bintrafusp alfa
  • Socazolimab
  • Erfonrilimab

Phase 23

  • Danburstotug
  • INCB-086550
  • Pacmilimab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • CytomX Therapeutics18%
    • ImmuneOncia Therapeutics Inc.18%
    • Incyte Biosciences Japan GK18%
    • Ir Innovate Research Private Limited18%
    • Jiangsu Alphamab Biopharmaceuticals Co., Ltd18%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Antibody1185%
    • Protein or peptide18%
    • Other18%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 8 of 13 act as: Programmed cell death 1 ligand 1 inhibitor; the rest name their own mechanism.
    DurvalumabApprovedAstraZeneca PharmaceuticalsAntibodyInhibitor—426—
    AtezolizumabApprovedRocheAntibodyInhibitor—408—
    AvelumabApprovedMerck KGaAAntibodyOtherProgrammed cell death 1 ligand 1 other70—
    SugemalimabApprovedAkeso BiopharmaAntibodyBinding agentProgrammed cell death 1 ligand 1 binding agent13—
    CosibelimabApprovedCheckpoint TherapeuticsAntibodyInhibitor—4—
    AdebrelimabPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.AntibodyInhibitor—262—
    EnvafolimabPhase 3Ir Innovate Research Private LimitedAntibodyBinding agentProgrammed cell death 1 ligand 1 binding agent49—
    Bintrafusp alfaPhase 3Merck KGaAProtein or peptideBinding agentProgrammed cell death 1 ligand 1 binding agent5—
    SocazolimabPhase 3Lee's PharmAntibodyInhibitor—1—
    ErfonrilimabPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdAntibodyInhibitor—0—
    DanburstotugPhase 2ImmuneOncia Therapeutics Inc.AntibodyInhibitor—1—
    INCB-086550Phase 2Incyte Biosciences Japan GKOtherInhibitor—0—
    PacmilimabPhase 2CytomX TherapeuticsAntibodyBinding agentProgrammed cell death 1 ligand 1 binding agent0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 56 in all, from ClinicalTrials.gov.
    A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCDurvalumabPhase 2Not yet recruitingAstraZeneca2026-11-17
    PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency GenesDurvalumabPhase 2Not yet recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest2026-11-16
    A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigAtezolizumabPhase 3Not yet recruitingBoehringer Ingelheim2026-11-10
    Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary SyndromeAtezolizumab, CosibelimabPhase 1Not yet recruitingCity of Hope Medical Center2026-11-09
    Retlirafusp Alfa or Adebrelimab Plus SOX as Neoadjuvant Therapy for HER2-Negative Resectable Gastric or Gastroesophageal Junction AdenocarcinomaAdebrelimabPhase 2Not yet recruitingQun Zhao2026-11-09
    Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJAdebrelimabPhase 2Not yet recruitingFudan University2026-11-03
    A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)DurvalumabPhase 3Not yet recruitingMerck Sharp & Dohme LLC2026-11-02
    A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted ImmunochemotherapyDurvalumabPhase 2RecruitingSamsung Medical Center2026-11-02
    Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung CancerAdebrelimabPhase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital2026-11-02
    Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal CancerAdebrelimabPhase 2Not yet recruitingHenan Cancer Hospital2026-10-30
    Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular CarcinomaAtezolizumab, Durvalumab—Not yet recruitingAssiut University2026-10-29
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerAtezolizumabPhase 2Not yet recruitingAbbVie2026-10-26
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung CancerAtezolizumabPhase 2Not yet recruitingAbbVie2026-10-26
    A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerAdebrelimabPhase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2026-10-26
    A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLCAdebrelimabPhase 3Not yet recruitingWest China Hospital2026-10-26
    A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLCAdebrelimabPhase 1Not yet recruitingHansoh BioMedical R&D Company2026-10-23
    A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and AdolescentsAdebrelimabPhase 1 / Phase 2Enrolling by invitationSecond Affiliated Hospital of Wenzhou Medical University2026-10-22
    PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerAtezolizumab, DurvalumabPhase 2RecruitingSamsung Medical Center2026-10-21
    GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)Durvalumab—Not yet recruitingAstraZeneca2026-10-20
    A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.DurvalumabPhase 3RecruitingAstraZeneca2026-10-16
    Maintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in ColombiaAtezolizumab—RecruitingFundación Santa Fe de Bogota2026-10-02
    First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainAvelumab—Active, not recruitingBristol-Myers Squibb2026-10-01
    A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)EnvafolimabPhase 2RecruitingThe Second Affiliated Hospital of Chongqing Medical University2026-10-01
    Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular CarcinomaAtezolizumabPhase 1 / Phase 2Not yet recruitingWest China Hospital2026-09-23
    SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLCEnvafolimabPhase 2Not yet recruitingThe First People's Hospital of Lianyungang2026-09-14
    Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionEnvafolimabNot applicableNot yet recruitingTianjin Medical University Cancer Institute and Hospital2026-07-30
    A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.EnvafolimabPhase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital2026-07-27
    Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCCSugemalimabPhase 2Active, not recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences2026-07-17
    Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract CancerEnvafolimabPhase 1 / Phase 2RecruitingWest China Hospital2026-06-09
    Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract MalignanciesEnvafolimabPhase 2Not yet recruitingSir Run Run Shaw Hospital2026-05-20
    Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access ProgramEnvafolimab—RecruitingIR INNOVATE RESEARCH PRIVATE LIMITED2026-05-01
    Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentEnvafolimabPhase 2RecruitingJian Li2026-04-30
    Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaAvelumabPhase 2Not yet recruitingGruppo Oncologico Italiano di Ricerca Clinica2026-03-10
    Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyCosibelimabPhase 4RecruitingDana-Farber Cancer Institute2026-02-23
    Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCSugemalimabNot applicableRecruitingPeking Union Medical College2025-11-25
    Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCAvelumabPhase 2RecruitingSamsung Medical Center2025-11-06
    Impact of Circadian Rhythm on ImmunotherapyAvelumabPhase 2RecruitingLiza Villaruz, MD2025-11-05
    Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized TrialSugemalimabPhase 1 / Phase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University2025-09-24
    DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaAvelumabPhase 2RecruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest2025-08-07
    Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung CancerSugemalimab—Not yet recruitingJi Yongling2025-06-25
    Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer PatientsSugemalimabPhase 2RecruitingShanghai Pulmonary Hospital, Shanghai, China2025-05-23
    Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal AdenocarcinomaCosibelimabPhase 1Not yet recruitingArsen Osipov2025-05-21
    Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothelial CancerAvelumabPhase 2RecruitingQueen Mary University of London2025-03-25
    Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.AvelumabPhase 2RecruitingGruppo Oncologico del Nord-Ovest2025-03-11
    Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid BiopsySugemalimab—RecruitingPeking University Cancer Hospital & Institute2025-03-11
    DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.AvelumabPhase 4RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS2025-02-11
    A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCSugemalimabPhase 3RecruitingAkeso2024-09-27
    Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical CancerSocazolimabPhase 3RecruitingLee's Pharmaceutical Limited2024-06-14
    Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCSugemalimabPhase 1 / Phase 2RecruitingSichuan University2024-01-22
    Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaBintrafusp alfaPhase 2Active, not recruitingInstitut Bergonié2021-05-05
    Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic CholangiocarcinomaBintrafusp alfaPhase 1Active, not recruitingM.D. Anderson Cancer Center2021-01-13
    TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapYBintrafusp alfaNot applicableRecruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2020-07-22
    Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaBintrafusp alfaPhase 2Active, not recruitingNational Cancer Institute (NCI)2020-06-05
    A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeDanburstotugPhase 2Active, not recruitingImmuneOncia Therapeutics Inc.2020-06-04
    Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary MalignanciesBintrafusp alfaPhase 1Active, not recruitingNational Cancer Institute (NCI)2020-01-22
    Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCosibelimabPhase 1Active, not recruitingCheckpoint Therapeutics, Inc.2017-07-11

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Non-small cell lung carcinoma
    0.68
    Merkel cell skin cancer
    0.64
    Small cell lung carcinoma
    0.62
    Neoplasm
    0.59
    Urothelial carcinoma
    0.59
    Head and neck squamous cell carcinoma
    0.59
    Urinary bladder carcinoma
    0.48
    Esophageal squamous cell carcinoma
    0.47
    Gastric adenocarcinoma
    0.47

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3580522, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9NZQ7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.